Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.
Medicine (Baltimore). 2021 Nov 5;100(44):e27705. doi: 10.1097/MD.0000000000027705.
Constipation is the most predominant symptom of Parkinson disease (PD), preceding the occurrence of motor symptoms in some patients, leading to reduced quality of life (QOL). The general approaches for the treatment have some side effects, but probiotics are live or attenuated microorganisms attributed to ameliorating constipation effects. Moreover, as treatments are generally well tolerated and side effects are scarce, there is room for further research. Therefore this work aims at investigating the clinical effectiveness and safety of probiotics for constipation in PD.
Published RCTs will be retrieved by searching Medline, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), VIP, Wan Fang database, and China Biology Medicine Database (complete bowel movement), which will be searched from establishment of the database to October 10, 2021. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines are used to design this protocol. RevMan V.5.3 software will be used for meta-analysis, risk of bias will be assessed by the Cochrane Collaboration tool and the collected evidence will be narratively synthesized. We will also perform a meta-analysis to pool estimates from studies considered to be homogenous. Subgroup analyses will be based on intervention or overall bias.
The meta-analysis will assess the effectiveness and safety of using probiotics to treat and heal the constipation of PD.
Ethics approval is unrequired.
CRD42021276215.
便秘是帕金森病(PD)最常见的症状,在某些患者中先于运动症状出现,导致生活质量(QOL)下降。一般的治疗方法有一些副作用,但益生菌是改善便秘效果的活的或减毒微生物。此外,由于治疗通常耐受性良好,副作用稀少,因此有进一步研究的空间。因此,这项工作旨在研究益生菌治疗 PD 便秘的临床疗效和安全性。
通过检索 Medline、Embase、Cochrane 图书馆、Web of Science、中国国家知识基础设施(CNKI)、VIP、万方数据库和中国生物医学文献数据库(完全排便),检索已发表的 RCT,检索时间为数据库建立至 2021 年 10 月 10 日。本研究采用系统评价和荟萃分析首选报告项目(PRISMA-P)指南进行设计。RevMan V.5.3 软件将用于荟萃分析,使用 Cochrane 协作工具评估偏倚风险,并对收集到的证据进行叙述性综合。我们还将进行荟萃分析,以汇总被认为同质的研究的估计值。亚组分析将基于干预或整体偏倚。
荟萃分析将评估使用益生菌治疗和治愈 PD 便秘的有效性和安全性。
不需要伦理批准。
CRD42021276215。